Business UpdateMay 29, 2026, 07:02 AM
Picard Medical Q1 Revenue +85%; Addresses NYSE Listing Notice
AI Summary
Picard Medical reported a transformational 2025 with total revenue up 12.5% to $4.9 million, followed by a strong start to 2026 with Q1 revenue growing 85% to $1.2 million and gross profit turning positive at a 24% margin. The company made significant progress in debt reduction and capital structure simplification, while also advancing its next-generation Emperor Total Artificial Heart, with animal testing successfully completed. However, Picard Medical received a notice from NYSE American regarding stockholders' equity requirements and is preparing a compliance plan, alongside an auditor's going-concern qualification for 2025.
Key Highlights
- 2025 total revenue reached $4.9 million, up 12.5%.
- Q1 2026 revenue grew 85% to $1.2 million.
- Q1 2026 gross profit turned positive at a 24% margin.
- Repaid $7.4 million senior secured debt in cash; settled $2.1 million via equity in Q1 2026.
- Raised an additional $5.0 million in gross proceeds through a public offering post-Q1.
- Successfully completed second-generation Emperor TAH animal testing last week.
- Received NYSE American notice regarding stockholders' equity; compliance plan due June 7, 2026.
Price Impact
More from PMI